Immunic publishes investor presentation outlining vidofludimus calcium Phase 3 program in multiple sclerosis

IMMUNIC INC

IMMUNIC INC

IMUX

0.00
  • Immunic positioned vidofludimus calcium (IMU-838) as its lead oral multiple sclerosis candidate, combining Nurr1 activation with selective DHODH inhibition.
  • Phase 3 ENSURE-1 and ENSURE-2 relapsing MS trials fully enrolled with 2,221 patients; top-line data expected by year-end 2026.
  • U.S. NDA submission targeted for mid-2027; potential U.S. regulatory approval projected in 2028.
  • Progressive MS expansion framed around Phase 2 CALLIPER signals on disability measures; Phase 3 program described as in preparation for later in 2026.
  • Funding expected into late 2027; U.S. intellectual property protection expected through 2044.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.